About XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi’s ID4 platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide.

Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since built an elite team with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi’s cutting-edge technologies, innovative solutions, and diverse applications across the pharmaceutical value chain have helped it gain industry approval and establish strategic partnerships with top international pharmaceutical companies.

Locations
Co-Founders
Milestones
Investors
Certification

Global BD Center

XtalPi’s Boston office, located in Kendall Square, Cambridge MA, is the company’s first location that opened shorty after its founding in 2014. Today, it has a team of scientists with extensive experience in quantum physics, computational chemistry, AI, and solid state research. In addition to being a research center for internal projects and external collaborations, the Boston office also serves as a business development center for clients in the US, Europe, and part of Asia.


245 Main St, 12th Floor, Cambridge, MA 02142

Wen Shuhao

Co-founder/Chairman

Dr. Shuhao Wen is the co-founder and chairman of the board at XtalPi, and an adjunct professor at Zhejiang University. Shuhao is a published quantum physicist with over 14 years of research experiences on multi-scale simulation technology, quantum-classical hybrid theory, and molecular crystal polymorphism ranking theory. Prior to founding XtalPi, Shuhao completed his postdoctoral research at the Massachusetts Institute of Technology (MIT) and worked as a postdoctoral research scholar at the University of California at Riverside. At UC Riverside, he participated in the development of the HMBI (Hybrid Many Body Interaction) approach, a highly accurate calculation model for molecular crystal. Shuhao has published 32 papers and is the holder of 5 patents and 3 PCT patents. He led the development and industrial application of XtalPi’s crystal structure prediction algorithm, which is an important technological advancement in this field.

Shuhao holds a Ph.D. in sciences from Chinese Academy of Sciences.

Ma Jian

Co-founder/CEO

Jian Ma, Ph.D., is co-founder and CEO of XtalPi, overseeing business operations as well as research and product development. Prior to founding XtalPi in 2014, Dr. Ma served as a postdoctoral associate at the Massachusetts Institute of Technology, and was visiting scholar at RIKEN in Japan and The Chinese University of Hong Kong, during which time he completed extensive research on quantum information, quantum computing, and numerical simulation. Dr. Ma has published over twenty peer-reviewed articles on top scholarly publications, including Physics Reports, Physical Reiview and Journal of Chemical Physics.

Dr. Ma earned his doctorate and B.S. in Physics at Zhejiang University.

Lai Lipeng

Co-founder and Head of AI

Lipeng has a diverse background in mathematics and physics, including particle physics, fluid dynamics, biophysics and complex networks. As XtalPi’s co-founder, he is currently leading the company’s Beijing team, which is focusing on the application of AI technologies in the development of new therapeutics. By integrating big data from biology and chemistry with deep learning algorithms, XtalPi aims to provide solutions that can e actively accelerate drug discovery. The team is also seeking in-depth collaboration projects with researchers to explore the potential of AI in fundamental research areas such as biology and chemistry.

Lipeng received his double B.S. degree in physics and mathematics from Peking University and his Ph.D. in physics from the University of Chicago. He was a SUTD- MIT graduate fellow at MIT when he co-founded XtalPi.

Co-Founders

Wen Shuhao

Co-founder/Chairman

Ma Jian

Co-founder/CEO

Lai Lipeng

Co-founder and Head of AI

2014

Milestones

  • May   Founded in the campus of MIT
  • Dec   Received angel investment

2015

Milestones

  • Sept   XtalPi (Shenzhen) was officially established
  • Oct   Cooperated with Roche (Shanghai) and acquired the first customer.
  • Nov   Launched the self-developed 1st-gen solid-state drug screening and design platform
  • Nov   Established a close partnership with AWS
  • Nov   Received the Series A funding round led by Tencent
  • Nov   XARC was established

2016

Milestones

  • Nov   R&D Center jointly established with universities yielded the first batch of important experimental results

2017

Milestones

  • March   Signed an R&D cooperation agreement with Pfizer and acquired a major account
  • July   Started joint R&D project with SSCI, a world-leading solid-state drug R&D organization
  • Oct   Successfully held the 1st AI + Pharmaceutical and Healthcare Innovation Summit

2018

Milestones

  • Jan   Received the Series B funding round of USD 15 million
  • May   Established strategic partnership with Pfizer
  • Sept   Selected into Top 50 Enterprise with Best Investment Value in China (4th place)
  • Sept   Shenzhen Longhua Experimental R&D Base officially opened
  • Oct   Received Series B+ funding round of USD 46 million
  • Nov   Rated as National Hi-Tech Enterprise
  • Nov   Approved to establish Shenzhen Academician Workstation

2019

Milestones

  • May   Obtained ISO27001 Information Security Management System Certificate
  • July   Selected into List of China's top influential Enterprises in Health Industry , won the title of Best Biomedical Innovation Enterprise
  • Oct   Rational Solid Form Design Summit

2019
2018
2017
2016
2015
2014

Investors

Qualifications and certificates

In May 2019, XtalPi obtained the ISO27001 certificates issued by UKAS (United Kingdom Accreditation Service) and CNAS (China National Accreditation Service for Conformity Assessment) respectively. ISO27001 is a management system centered on information asset security and business risk management. It is the most widely accepted and applied system certification standard in the field of information security. Obtaining this certificate indicates that the company has established a scientific and effective information security management system to provide users with safe and reliable information services.

  • In May 2019, XtalPi obtained the ISO27001 certificates issued by UKAS (United Kingdom Accreditation Service) and CNAS (China National Accreditation Service for Conformity Assessment) respectively. ISO27001 is a management system centered on information asset security and business risk management. It is the most widely accepted and applied system certification standard in the field of information security. Obtaining this certificate indicates that the company has established a scientific and effective information security management system to provide users with safe and reliable information services.